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http://dxAbstract: Tapentadol may have a lower abuse risk than other opioids because it has a relatively low
affinity for the mu-opioid receptor. The aim of this retrospective cohort study was to compare the risk
of opioid abuse between tapentadol immediate release (IR) and oxycodone IR using 2 claims databases
(OptumandMarketScan). Subjectswith no recent opioid use exposed to tapentadol IR or oxycodone IR
in 2010 were followed for 1 year. The outcome was the proportion of subjects who developed opioid
abuse, defined as subjects with International Classification of Diseases, 9th revision, codes for opioid
abuse, addiction, or dependence. The relative odds of abusewere estimated using a logistic regression
model with propensity-score stratification. The estimates from the 2 databases were pooled using a
random effects model. There were 13,814 subjects in Optum (11,378 exposed to oxycodone,
2,436 exposed to tapentadol) and 25,553 in MarketScan (21,728 exposed to oxycodone, 3,825 exposed
to tapentadol). The risk of abuse was higher in the oxycodone group than in the tapentadol group in
each database. The pooled adjusted estimate for the odds of abuse was 65% lower with tapentadol
than with oxycodone (odds ratio = .35, 95% confidence interval = .21–.58). The risk of receiving an
abuse diagnosis with tapentadol was lower than the risk with oxycodone. Continued monitoring is
warranted because opioid desirability can change over time.
Perspective: This study compared the risk of receiving an opioid abuse diagnosis between
tapentadol and oxycodone in 2 U.S. claims databases. The risk of receiving an abuse diagnosis was
lower with tapentadol during the year of follow-up. Opioid prescribers and patients must be aware
of the risk of abuse associated with all opioids.
ª 2013 by the American Pain Society
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he burden of pain is a significant public health
problem. The Institute of Medicine reported in
2011 that chronic pain affects millions of adults in
the United States, more than the total affected by heart
disease, cancer, and diabetes combined,17 and that
uncontrolled pain substantially reduces quality of life
and productivity.17 Opioids are increasingly prescribed
for the treatment of painful chronic conditions,20 but
there is growing concern about the risk of opioid abuse,
diversion,10,20 overdose, and death.3,32,36,40
The mechanism of action of an opioid could influence
its risk of abuse.21,43,44 Tapentadol is an opioid with 2
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.doi.org/10.1016/j.jpain.2013.05.010inhibits the reuptake of norepinephrine.19 Tapentadol
has an 18-fold lower affinity for the mu-opioid receptor
than morphine.39 Because the activation of the mu-
opioid receptor is responsible for the mood alterations
and the euphoria associated with opioids, the risk of
abuse associated with tapentadol may be expected to
be lower than with other opioids. Limited evidence
from population-based studies also suggests that the
risk of abuse of tapentadol may be lower than other
opioids. Opioid doctor shopping, that is, obtaining
opioid prescriptions from multiple prescribers,7,8 which
is a way in which opioids may be abused and their use
diverted,3,26,35 is much less commonly observed in
opioid-na€ıve subjects initially exposed to tapentadol
than in opioid-na€ıve subjects initially exposed to
oxycodone.9 Similarly, data from internet monitoring,
surveillance of addiction treatment centers, pharma-
covigilance efforts, and surveys of college students
suggest that the risk of abuse of tapentadol is lower
than that of other Schedule II opioids.11,12 However,
there are no studies that explicitly compare the risk of
opioid abuse and addiction in subjects prescribed1227
Table 1. Codes Used to Identify Opioid Abuse,
Dependence, and Addiction
CODE DESCRIPTION
305.50 Opioid abuse, unspecified use
305.51 Opioid abuse, continuous use
305.52 Opioid abuse, episodic use
304.00 Opioid type dependence, unspecified use
304.01 Opioid type dependence, continuous use
304.02 Opioid type dependence, episodic use
304.70 Combinations of opioid type drug with any other drug
dependence, unspecified use
304.71 Combinations of opioid type drug with any other drug
dependence, continuous use
304.72 Combinations of opioid type drug with any other drug
dependence, episodic use
4306 F Patient counseled regarding psychosocial AND
pharmacologic treatment options for opioid
addiction
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compare the risk of opioid abuse between tapentadol
immediate release (IR) and oxycodone IR.
Methods
We conducted a retrospective cohort study using 2 U.S.
claims databases (Optum and MarketScan), which are
commonly used for pharmacoepidemiologic research.
The Optum Clinformatics database represents a privately
insured population and captures administrative claims
primarily from the UnitedHealth Group; it has at least
36 million members with both medical and pharmacy
benefits. The MarketScan Commercial Claims and En-
counters database represents a privately insured popula-
tion and captures administrative claims from inpatient
and outpatient visits and pharmacy claims of large
employers and multiple insurance plans. The data set
used for this study contains more than 90 million
individuals with medical and pharmacy coverage from
January 2000 to January 2012.
Inclusion Criteria
Subjects with no recent opioid use whose first opioid
exposure was to tapentadol IR or oxycodone IR in 2010
were included and observed for 1 year. Subjects with
no recent opioid use were those with no opioid
dispensing during the 3 months before the index date.
The index date was the date of the first dispensing of
tapentadol or oxycodone. Subjects were required to
have been in the database for at least 3 months prior
to their index date and for at least 12 months after.
The codes used to identify tapentadol IR and oxycodone
IR are listed in Appendix 1.
One year of follow-up was selected because studies
assessing shopping behavior suggest that 75%of the sub-
jectswhodevelopedshoppingbehaviorhad thefirstevent
#261 days after first exposurewith amedian of 234 days.8
Exclusion Criteria
Subjects with a history of opioid abuse, opioid addic-
tion, or opioid dependence at any time before the index
date, as well as subjects who filled a prescription for an
opioid other than the indexed opioid before the index
date or within the next 3 days, were excluded.
Outcome
Theoutcomeof interestwas incident reporteddiagnosis
of opioid abuse, opioid addiction, or opioid dependence
after the index date. The list of the International Classi-
fication of Diseases, 9th revision (ICD-9), Healthcare
Common Procedure Coding System, and Current Proce-
dural Terminology codes used is found in Table 1.
Confounders
To control for theeffectofbaselinedifferencesbetween
the subjects exposed to tapentadol and those exposed
to oxycodone, propensity score stratification was used.
Propensity score is the conditional probability of a
subject’s receiving aparticular exposure, in this case, initialexposure to tapentadol versus oxycodone, given a set of
confounders. To calculate the propensity score, the con-
founders were included in a logistic regression model to
predict the exposure, without including the outcome.5,6
As a result, the collection of confounders was collapsed
into a single variable, the probability (propensity) of
being initially exposed to tapentadol versus oxycodone.
Subjects initially exposed to tapentadol and subjects
initially exposed to oxycodone who have the same value
of propensity score (regardless of the treatment they
actually received) will have the same probability of
receiving one initial treatment or the other.
Propensity Score
It has been shown that models that automatically
select the variables to calculate the propensity score
can reduce bias relative to the models that use only a
predefined group of variables.24,27,30 Therefore, we
supplemented a defined set of a priori confounders
with additional covariates for all medical conditions
and drugs. The known confounders were age, gender,
state, quarter of the year of the index date, year, time
in the database before the index date, major
depression, mood disorders, anxiety disorders, abuse of
nonopioid medications (such as alcohol or tobacco),
and use of benzodiazepines. The ICD-9 codes used
to define these conditions are listed in Appendix 2.
In addition, binary covariates were added for each
medical condition, based on a diagnosis of the
condition in the prior 3 months, as represented by the
227 unique high level group terms with the Medical
Dictionary for Regulatory Activities (MedDRA) vocabu-
lary (eg, coronary artery disorders). Eighty-two
covariates were also included for each drug class,
as represented by 2-digit codes within the Anato-
mical Therapeutic Chemical classification system
(eg, diuretics) if any drug within the class was dispensing
during the 3 months prior to the index date. The Obser-
vational Medical Outcomes Partnership vocabulary was
used to map ICD-9 codes to MedDRA high level group
terms and National Drug Codes into Anatomical Thera-
peutic Chemical classification.14,28,34
Cepeda et al The Journal of Pain 1229Major depression, mood and anxiety disorders, and
abuse of nonopioid medications, such as alcohol or
tobacco, and pain-related diagnoses were not mapped to
MedDRA concepts to allow for more specificity.
Pain diagnoses were included as arthritis, back pain,
fractures, headache, malignancies, musculoskeletal pain,
neuropathic pain, other, reproductive systempain, visceral
pain, andwound/injuryusingpublished ICD-9groupings.31
The propensity score was estimated using Bayesian
logistic regression.18 We used a Laplace distribution for
the prior and cross validation to obtain the variance.
Checking Balancing Properties of the
Propensity Score
To check the balancing properties of the propensity
score, we tabulated the pain-related conditions and
the other variables known to be associated with opioid
abuse in each treatment group and calculated standard-
ized differences of means or proportions in each of
the quintiles of the propensity scores and overall. To
calculate the overall standardized difference for each
potential confounder, we averaged the standardized
differences of the propensity score quintiles for that
potential confounder. Standardized differences of less
than .25 are an indication of appropriate balance.33
Outcome Model
The relative risk of opioid abuse between tapentadol
and oxycodone was estimated using a logistic regressionFigure 1. Flow diagram in Optum database. Numbers represent s
The percentages use the number of exposed patients as denominatmodel, with the binary indicator of incident opioid abuse
diagnosis as the outcome variable and the exposure
status and propensity score quintiles as covariates. The
estimates from the 2 databases were then pooled using
a random effects model. Odds ratios (ORs) and 95%
confidence intervals (CIs) are reported. For outcomes of
low frequency, as is the case with abuse, odds closely
approximate risks, so we refer to the more familiar
term, risk. Oxycodone was used as the referent group
such that ORs <1 indicate a lower risk of an abuse
diagnosis with tapentadol.Dose Assessment
Daily dose of opioid at baseline was calculated and to
allow comparison converted into tapentadol equivalent
doses using a 5:1 conversion ratio.2Sample Size
Approximately 1,000 subjects initially exposed to
tapentadol were needed to detect a 2-fold decrease in
the risk of abuse, assuming a 3% risk of abuse among
those who were initially exposed to oxycodone,15
with 80% power, an alpha error of 5%, and a ratio of
oxycodone to tapentadol subjects of 10:1.Sensitivity Analyses
We evaluated the robustness of the propensity score
model by performing the analysis with and withoutubjects who failed to meet each one of the inclusion criteria.
ors.
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scores.34 We also performed matching as an alternative
propensity score adjustment strategy to stratification.
We implemented a nearest availablematching algorithm
with a 1:1 tapentadol to oxycodone ratio in the
Optum database and, because of the larger sample
size, a 1:2 match in the MarketScan database, and a pro-
pensity score difference smaller than .1. We then built a
conditional logistic regression to obtain the relative risk
of opioid abuse diagnosis between tapentadol and oxy-
codone while respecting the matches.
The analyses were conducted using SAS, version 9.3
(SAS Institute Inc, Cary, NC). The New England Institu-
tional Review Board determined that this study was not
human subjects research and was exempt from review.Results
There were 13,814 subjects from the Optum database
who met the inclusion criteria (11,378 initially exposed
to oxycodone, 2,436 to tapentadol) and 25,553 subjects
from the MarketScan database who met the inclusion
criteria (21,728 initially exposed to oxycodone, 3,825 to
tapentadol). Figs 1 and 2 show the number of subjects
who failed to meet each one of the inclusion criteria in
each of the databases.
In each database, subjects in the tapentadol group
were older, more likely to be women, and more likelyFigure 2. Flow diagram in MarketScan database. Numbers represen
The percentages use the number of exposed patients as denominatto have back pain than subjects in the oxycodone group
(Table 2).
The daily dose of opioid at baseline was slightly higher
in the tapentadol group than in the oxycodone group in
both databases. The median tapentadol equivalent daily
dose in the tapentadol group was 300.0 mg versus
250.0mg in the oxycodone group in theOptumdatabase
and 300.0 mg versus 214.3 mg in the MarketScan
database. There was no observed difference in other
opioid use between the tapentadol and oxycodone
groups, and the majority of persons in each cohort had
no other opioid use (25th–75th percentile, 0–2).
The models to calculate the propensity score included
365 variables in the Optum database and 370 variables in
the MarketScan database. After stratification on the
propensity score, most standardized differences in
baseline characteristics got smaller (Table 2), indicating
that a better balance was achieved. Similarly, the
standardized differences for each one of the con-
founders in each one of the quintiles of the propensity
score were very small, especially in the first 4 propensity
score categories in each database, confirming the
good balance achieved with the propensity score
(Appendixes 3 and 4).
In each database, a higher percentage of subjects in
the oxycodone group than in the tapentadol group
received opioid abuse diagnoses. After adjustment, the
risk of developing an opioid abuse diagnosis remainedt subjects who failed to meet each one of the inclusion criteria.
ors.
Table 2. Baseline Characteristics of Subjects Exposed to Tapentadol and Oxycodone With Standardized Differences Before and After
Propensity Score Adjustment
CHARACTERISTIC
OPTUM DATABASE MARKETSCAN DATABASE
OXYCODONE TAPENTADOL
STANDARDIZED
DIFFERENCE
BEFORE
PROPENSITY SCORE
STANDARDIZED
DIFFERENCE
AFTER PROPENSITY
SCORE OXYCODONE TAPENTADOL
STANDARDIZED
DIFFERENCE BEFORE
PROPENSITY SCORE
STANDARDIZED DIFFERENCE
AFTER PROPENSITY SCORE
Number of subjects 11378 2436 21728 3825
Age, mean 6 SD 43.79 6 17.65 47.52 6 12.90 .24 .04 42.12 6 15.51 46.17 6 11.59 .30 .07
Women, n (%) 5858 (51.49) 1574 (64.61) .27 .01 11905 (54.79) 2492 (65.15) –.21 .01
Variable, n (%)
Arthritis 2935 (25.80) 665 (27.30) .03 .10 5229 (24.07) 942 (26.63) .01 .08
Back pain 1708 (15.01) 552 (22.66) .20 .09 2834 (13.08) 867 (22.67) .25 .09
Benzodiazepine use 1434 (12.60) 413 (16.95) .12 .08 2934 (13.50) 716 (18.72) .14 .11
Drug abuse excluding opioids 569 (5.00) 72 (2.96) –.09 .26 622 (2.86) 54 (1.41) –.07 .06
Mood/anxiety disorders and depression 1173 (10.31) 266 (10.92) .02 .15 2165 (9.96) 374 (9.78) –.01 .09
Fractures 849 (7.46) 74 (3.04) –.18 .01 1447 (6.66) 92 (2.41) –.18 –.13
Headaches 639 (5.62) 133 (5.46) –.01 .06 970 (4.46) 175 (4.58) .01 –.07
Malignancy 2650 (23.29) 490 (20.11) –.08 –.14 4354 (20.04) 586 (15.32) –.12 .00
Musculoskeletal pain 2946 (25.89) 723 (29.68) .08 .13 4927 (22.68) 971 (25.39) .06 .16
Other 229 (2.01) 54 (2.22) .01 .01 278 (1.28) 40 (1.05) –.01 .00
Reproductive system pain 249 (2.19) 64 (2.63) .02 –.04 458 (2.11) 80 (2.09) .00 –.02
Visceral pain 1764 (15.50) 207 (8.50) –.22 .08 2843 (13.08) 294 (7.69) –.18 –.09
Wound injury 458 (4.03) 37 (1.52) –.12 .22 827 (3.81) 42 (1.10) –.12 –.07
Neuropathy 302 (2.65) 139 (5.71) .14 .05 520 (2.39) 139 (3.63) .06 .01
Abbreviation: SD, standard deviation.
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Table 3. Subjects Who Developed Opioid Abuse Diagnosis in the Tapentadol and Oxycodone
Groups: Unadjusted and Adjusted OR
DATABASE
OXYCODONE
IR N (%)
TAPENTADOL
IR N (%)
UNADJUSTED
OR (95% CI)
ADJUSTED OR
(95% CI)
ADJUSTED OR
AFTER EXCLUDING
SUBJECTS WITHOUT
COMPLETE PROPENSITY SCORE
OVERLAP (95% CI)
ADJUSTED OR
AFTER MATCHING ON
PROPENSITY SCORE
(95% CI)
Optum
Abuse 75 (.66) 7 (.29) .43 (.1–.94) .26 (.12–.59) .28 (.12–.62) .20 (.08–.54)
No abuse 11303 (99.34) 2429 (99.71)
MarketScan
Abuse 105 (.48) 12 (.31) .65 (.32–1.2) .42 (.22–.79) .45 (.23–.85) .33 (.14–.79)
No abuse 21623 (99.52) 3813 (99.69)
1232 The Journal of Pain Risk of Abuse Between Tapentadol and Oxycodonehigher in the oxycodone group than in the tapentadol
group in each database (Table 3). Overall, the risk of
developing abuse diagnoses was much smaller with
tapentadol than with oxycodone (pooled estimate for
abuse, OR = .35, 95% CI = .21–.58; Fig 3).
The sensitivity analyses provided similar results to the
main analyses. After excluding subjects without
complete propensity score overlap, 10,111 subjects
initially exposed to oxycodone and 2,434 subjects initially
exposed to tapentadol in theOptumdatabaseand19,013
subjects initially exposed to oxycodone and 3,806 sub-
jects initially exposed to tapentadol in the MarketScan
databasewere included in theanalyses. The standardized
differences in each of the quintiles of the propensity
score were similarly small compared with the ones in
the main analysis. As in the main analyses, the risk of
developing an abuse diagnosis was much smaller in
subjects exposed to tapentadol than in subjects exposed
to oxycodone in each database (Table 3).
The results after matching were similar to the main
analyses as well. In the Optum database, a total of 4,018
subjects were matched, half initially exposed to tapenta-
dol and half to oxycodone. In the MarketScan database,
5,817 subjects were matched, 1,939 initially exposed toFigure 3. Meta-analysis of the risk of opioid abuse diagnosis of t
estimate for abuse obtained in a database with its 95% CI. The siz
diamond represents the overall effect estimate. The risk of abuse wtapentadol and 3,878 to oxycodone. The risk of devel-
oping an abuse diagnosis wasmuch smallerwith tapenta-
dol than with oxycodone in each of the databases:
OR = .20, 95% CI = .08–.54, in the Optum database and
OR = .33, 95% CI = .14–.79, in the MarketScan database.Discussion
The odds of receiving an abuse diagnosis among those
who initiated opioid use with tapentadol IR was 65%
lower than the risk of receiving an abuse diagnosis
among those who initiated opioid use with oxycodone
IR. The fact that the risk of receiving an abuse diagnosis
with tapentadol was similarly low in the 2 claims data-
bases and that the results remained similar in the sensi-
tivity analyses provide confidence in the findings of the
study. The relatively low affinity of tapentadol for the
mu-opioid receptor may explain its lower abuse risk.
The observed lower risk of receiving an abuse diag-
nosis associated with tapentadol in this study aligns
with its lower risk of opioid doctor shopping behavior.9
A retrospective cohort study in a longitudinal prescrip-
tion database compared the risk of opioid doctor
shopping behavior between opioid-na€ıve patients whoapentadol IR and oxycodone IR. Each line presents the relative
e of the box represents the weight given to that estimate. The
ith tapentadol is lower than the risk of abuse with oxycodone.
Cepeda et al The Journal of Pain 1233initiated opioid use with tapentadol IR and those who
initiated with oxycodone IR and found that the risk of
opioid doctor shopping (subjects with overlapping
opioid prescriptions written by different prescribers
and filled at $3 pharmacies) was 72% lower in subjects
exposed to tapentadol than in subjects exposed to
oxycodone (OR = .28, 95% CI = .22–.35).9 The relative
reductions in the risks of opioid doctor shopping
behavior and receiving an opioid abuse diagnosis are
of similar magnitude. The results of the present study
also align with data from pharmacovigilance studies,
which suggest a lower risk of abuse.11 One of these
studies included an assessment of the street price of
tapentadol, which was found to be one-tenth the street
price of oxycodone on a per-milligram basis,37 or half the
street price of oxycodone after adjustment for potency.
These overall findings provide reassurance that the
lower risk of receiving an abuse diagnosis of tapentadol
is neither the result of a peculiarity of a particular
database nor the endpoint assessed.
The findings of lower risks of shopping behavior and
receiving an abuse diagnosis associated with tapentadol
are in contrast with results of a likeability study that
showed that in opioid-experienced individuals, the sub-
jective effects of tapentadol were comparable to the
subjective effects of oral hydromorphone, and with ani-
mal data studies that showed that tapentadol exhibited
rewarding and reinforcing effects that were similar to
the ones produced by other opioids.22 The different
contexts in which these studies were performed, and
the different types of subjects included in these studies,
may contribute to the disparity of their findings.
Tapentadol IR was launched in 2009 and has been on
the U.S. market for much less time than oxycodone IR. It
could be argued that there might have not been enough
time for abusers to experiment with tapentadol. Data
from the Researched Abuse, Diversion and Addiction-
Related Surveillance, a surveillance system that monitors
the abuse, misuse, and diversion of prescription opioids,
suggest that abuse can be seen very soon after a new
opioid is marketed.13 Nonetheless, definitive proof
for the lower risk of abuse of tapentadol will need to
await longer experience with tapentadol because the
desirability of an opioid can change over time.13
Limitations
The ICD-9 codes we used to define abuse diagnosis
included codes for opioid dependence as well as abuse.
Opioid dependence does not necessarily imply abuse.
Opioid abuse has been defined as the use of an opioidfor psychic effects or any harmful use of the opioid.42 In
contrast, opioid dependence is a state of adaptation
that is manifested by withdrawal syndrome, diminution
of the analgesic effect over time (tolerance), or dose
escalation.1,4,29,42 However, many physicians use the
terms ‘‘opioid abuse,’’ ‘‘opioid addiction,’’ and ‘‘opioid
dependence’’ interchangeably, and other studies that
haveassessedopioidabusecombinedthecodesaswell.15,16
Despite the fact that the codes for abuse and
dependence are combined, opioid abuse is likely to be
underascertained in claims databases. Potential reasons
for underrecording of abuse include lack of recognition
of the condition; reluctance toput apotentially damaging
diagnosis in the patient’s record, especially in the absence
of certainty; and, because claims databases were devel-
oped to facilitate commercial transactions, the fact that
reimbursement considerations could affect which diag-
nosis codes to use.25
The incidenceofopioidabusediagnosis inour studywas
.6%. Though similar to the incidence reported in other
claims database studies,41 this abuse rate is more than 10
times lower thanwhat has been reported in past prospec-
tive studies (range, 5–31%).23,38 In our current study, we
observed an absolute risk reduction of #.5%. If the true
incidence of abuse is in fact 10 times higher, then the
impact on the absolute risk reduction could be 10 times
greater. In contrast, as long as the underreporting is
similar in the 2 groups, the extent of underestimation
does not bias the odds ratios reported in our study.
The findings of this study represent a privately
insured population and therefore may not generalize
to other populations of interest, such as the elderly or
the uninsured.
Physicians prescribed tapentadol or oxycodone to the
patients for clinical indications, and therefore patients
were not randomized. We controlled for the effect of
potential confounders through propensity score adjust-
ment, which permits the inclusion of a large number of
confounders. The balancing properties of the propensity
score are well known, but limited to the confounders
included in the models. Therefore, unobserved baseline
differences cannot be ruled out and those differences
could explain the results.
In summary, subjects who initiated opioid treatment
with tapentadol IR had a lower risk of receiving an opioid
abuse/dependence diagnosis than subjects who initiated
opioid treatment with oxycodone IR. However, the risk
withtapentadol IR isnotabsent.Opioidprescribers andpa-
tientsmustbeawareof the riskof abuseassociatedwithall
opioids and of changes in opioid desirability over time.References
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Appendix 1. List of Codes to Identify Tapentadol IR and Oxycodone IR
OXYCODONE TAPENTADOL
Oxycodone 5 MG Oral Tablet [M-Oxy] Tapentadol 50 MG Oral Tablet
Oxycodone 20 MG/ML Oral Solution [Oxydose] Tapentadol 75 MG Oral Tablet
Oxycodone 5 MG Oral Capsule [Oxynorm] Tapentadol 100 MG Oral Tablet
Oxycodone 5 MG Oral Capsule [Oxyrapid] Tapentadol 100 MG Oral Tablet [Nucynta]
Oxycodone Hydrochloride 1 MG/ML Oral Solution Tapentadol 50 MG Oral Tablet [Nucynta]
Oxycodone Hydrochloride 1 MG/ML Oral Solution [Roxicodone] Tapentadol 75 MG Oral Tablet [Nucynta]
Oxycodone Hydrochloride 10 MG Oral Capsule
Oxycodone Hydrochloride 10 MG Oral Tablet
Oxycodone Hydrochloride 10 MG Oral Tablet [Dazidox]
Oxycodone Hydrochloride 10 MG/ML Oral Solution
Oxycodone Hydrochloride 15 MG Oral Tablet
Oxycodone Hydrochloride 15 MG Oral Tablet [Roxicodone]
Oxycodone Hydrochloride 20 MG Oral Capsule
Oxycodone Hydrochloride 20 MG Oral Tablet
Oxycodone Hydrochloride 20 MG Oral Tablet [Dazidox]
Oxycodone Hydrochloride 20 MG/ML Oral Solution
Oxycodone Hydrochloride 20 MG/ML Oral Solution [ETH-Oxydose]
Oxycodone Hydrochloride 20 MG/ML Oral Solution [Oxyfast]
Oxycodone Hydrochloride 20 MG/ML Oral Solution [Roxicodone]
Oxycodone Hydrochloride 30 MG Oral Tablet
Oxycodone Hydrochloride 30 MG Oral Tablet [Roxicodone]
Oxycodone Hydrochloride 5 MG Oral Capsule
Oxycodone Hydrochloride 5 MG Oral Capsule [Oxy IR]
Oxycodone Hydrochloride 5 MG Oral Tablet
Oxycodone Hydrochloride 5 MG Oral Tablet [Endocodone]
Oxycodone Hydrochloride 5 MG Oral Tablet [Percolone]
Oxycodone Hydrochloride 5 MG Oral Tablet [Roxicodone]
Oxycodone Hydrochloride 5 MG Oral Tablet [Oxecta]
Oxycodone Hydrochloride 7.5 MG Oral Tablet
Oxycodone Hydrochloride 7.5 MG Oral Tablet [Oxecta]
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Appendix 2. List of Codes to Known Confounders: Drug Abuse Excluding Opioids and Mood and Anxiety Disorders and Depression
DRUG ABUSE EXCLUDING OPIOIDS ICD-9
MOOD AND ANXIETY
DISORDERS AND DEPRESSION ICD-9
Alcohol dependence syndrome 303 Mood disorder in conditions classified elsewhere 293.83
Acute alcoholic intoxication 303.0 Anxiety disorder in conditions classified elsewhere 293.84
Acute alcoholic intoxication in alcoholism, unspecified drinking behavior 303.00 Bipolar I disorder single manic episode 296.0
Acute alcoholic intoxication in alcoholism, continuous drinking behavior 303.01 Manic disorder, single episode, unspecified degree 296.00
Acute alcoholic intoxication in alcoholism, episodic drinking behavior 303.02 Bipolar I disorder, single manic episode, mild 296.01
Acute alcoholic intoxication in alcoholism, in remission 303.03 Bipolar I disorder, single manic episode, moderate 296.02
Other and unspecified alcohol dependence 303.9 Bipolar I disorder, single manic episode, severe, without mention of psychotic behavior 296.03
Other and unspecified alcohol dependence, unspecified drinking behavior 303.90 Bipolar I disorder, single manic episode, severe, specified as with psychotic behavior 296.04
Other and unspecified alcohol dependence, continuous drinking behavior 303.91 Bipolar I disorder, single manic episode, in partial or unspecified remission 296.05
Other and unspecified alcohol dependence, episodic drinking behavior 303.92 Manic disorder, single episode, in full remission 296.06
Other and unspecified alcohol dependence, in remission 303.93 Manic disorder recurrent episode 296.1
Drug dependence 304 Manic disorder, recurrent episode, unspecified degree 296.10
Sedative hypnotic or anxiolytic dependence 304.1 Manic disorder, recurrent episode, mild degree 296.11
Sedative, hypnotic or anxiolytic dependence, unspecified 304.10 Manic disorder, recurrent episode, moderate degree 296.12
Sedative, hypnotic or anxiolytic dependence, continuous 304.11 Manic disorder, recurrent episode, severe degree, without mention of psychotic behavior 296.13
Sedative, hypnotic or anxiolytic dependence, episodic 304.12 Manic disorder, recurrent episode, severe degree, specified as with psychotic behavior 296.14
Sedative, hypnotic or anxiolytic dependence, in remission 304.13 Manic disorder, recurrent episode, in partial or unspecified remission 296.15
Cocaine dependence 304.2 Manic disorder, recurrent episode, in full remission 296.16
Cocaine dependence, unspecified use 304.20 Major depressive disorder single episode 296.2
Cocaine dependence, continuous use 304.21 Major depressive disorder, single episode, unspecified degree 296.20
Cocaine dependence, episodic use 304.22 Major depressive disorder, single episode, mild degree 296.21
Cocaine dependence, in remission 304.23 Major depressive disorder, single episode, moderate degree 296.22
Cannabis dependence 304.3 Major depressive disorder, single episode, severe degree, without mention of psychotic behavior 296.23
Cannabis dependence, unspecified use 304.30 Major depressive disorder, single episode, severe degree, specified as with psychotic behavior 296.24
Cannabis dependence, continuous use 304.31 Major depressive disorder, single episode, in partial or unspecified remission 296.25
Cannabis dependence, episodic use 304.32 Major depressive disorder, single episode in full remission 296.26
Cannabis dependence, in remission 304.33 Major depressive disorder recurrent episode 296.3
Amphetamine and other psychostimulant dependence 304.4 Major depressive disorder, recurrent episode, unspecified degree 296.30
Amphetamine and other psychostimulant dependence, unspecified use 304.40 Major depressive disorder, recurrent episode, mild degree 296.31
Amphetamine and other psychostimulant dependence, continuous use 304.41 Major depressive disorder, recurrent episode, moderate degree 296.32
Amphetamine and other psychostimulant dependence, episodic use 304.42 Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behavior 296.33
Amphetamine and other psychostimulant dependence, in remission 304.43 Major depressive disorder, recurrent episode, severe degree, specified as with psychotic behavior 296.34
Hallucinogen dependence 304.5 Major depressive disorder, recurrent episode, in partial or unspecified remission 296.35
Hallucinogen dependence, unspecified use 304.50 Major depressive disorder, recurrent episode, in full remission 296.36
Hallucinogen dependence, continuous use 304.51 Bipolar affective disorder, manic, unspecified degree 296.40
Hallucinogen dependence, episodic use 304.52 Bipolar I disorder, most recent episode (or current) manic, mild 296.41
Hallucinogen dependence, in remission 304.53 Bipolar I disorder, most recent episode (or current) manic, moderate 296.42
Other specified drug dependence 304.6 Bipolar I disorder, most recent episode (or current) manic, severe, without mention of psychotic behavior 296.43
Other specified drug dependence, unspecified use 304.60 Bipolar I disorder, most recent episode (or current) manic, severe, specified as with psychotic behavior 296.44
Other specified drug dependence, continuous use 304.61 Bipolar I disorder, most recent episode (or current) manic, in partial or unspecified remission 296.45
Other specified drug dependence, episodic use 304.62 Bipolar I disorder, most recent episode (or current) manic, in full remission 296.46
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Appendix 2. Continued
DRUG ABUSE EXCLUDING OPIOIDS ICD-9
MOOD AND ANXIETY
DISORDERS AND DEPRESSION ICD-9
Other specified drug dependence, in remission 304.63 Bipolar affective disorder, depressed, unspecified degree 296.50
Combinations of drug dependence excluding opioid type drug, unspecified use 304.80 Bipolar I disorder, most recent episode (or current) depressed, mild 296.51
Combinations of drug dependence excluding opioid type drug, continuous use 304.81 Bipolar I disorder, most recent episode (or current) depressed, moderate 296.52
Combinations of drug dependence excluding opioid type drug, episodic use 304.82 Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior 296.53
Combinations of drug dependence excluding opioid type drug, in remission 304.83 Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior 296.54
Unspecified drug dependence 304.9 Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission 296.55
Unspecified drug dependence, unspecified use 304.90 Bipolar I disorder, most recent episode (or current) depressed, in full remission 296.56
Unspecified drug dependence, continuous use 304.91 Bipolar I disorder, most recent episode (or current) mixed, unspecified 296.60
Unspecified drug dependence, episodic use 304.92 Bipolar I disorder, most recent episode (or current) mixed, mild 296.61
Unspecified drug dependence, in remission 304.93 Bipolar I disorder, most recent episode (or current) mixed, moderate 296.62
Nondependent abuse of drugs 305 Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior 296.63
Alcohol abuse 305.0 Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior 296.64
Alcohol abuse, unspecified drinking behavior 305.00 Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission 296.65
Alcohol abuse, continuous drinking behavior 305.01 Bipolar affective disorder, mixed, in full remission 296.66
Alcohol abuse, episodic drinking behavior 305.02 Bipolar I disorder, most recent episode (or current) unspecified 296.7
Alcohol abuse, in remission 305.03 Bipolar disorder, unspecified 296.80
Tobacco use disorder 305.1 Atypical manic disorder 296.81
Cannabis abuse 305.2 Atypical depressive disorder 296.82
Cannabis abuse, unspecified use 305.20 Other and unspecified bipolar disorders 296.89
Cannabis abuse, continuous use 305.21 Unspecified episodic mood disorder 296.90
Cannabis abuse, episodic use 305.22 Other specified episodic mood disorder 296.99
Cannabis abuse, in remission 305.23 Depressive type psychosis 298.0
Hallucinogen abuse 305.3 Anxiety states 300.0
Hallucinogen abuse, unspecified use 305.30 Anxiety state, unspecified 300.00
Hallucinogen abuse, continuous use 305.31 Panic disorder without agoraphobia 300.01
Hallucinogen abuse, episodic use 305.32 Generalized anxiety disorder 300.02
Hallucinogen abuse, in remission 305.33 Other anxiety states 300.09
Sedative hypnotic or anxiolytic abuse 305.4 Agoraphobia with panic disorder 300.21
Sedative, hypnotic or anxiolytic abuse, unspecified 305.40 Agoraphobia without mention of panic attacks 300.22
Sedative, hypnotic or anxiolytic abuse, continuous 305.41 Social phobia 300.23
Sedative, hypnotic or anxiolytic abuse, episodic 305.42 Dysthymic disorder 300.4
Sedative, hypnotic or anxiolytic abuse, in remission 305.43 Affective personality disorder 301.1
Cocaine abuse 305.6 Affective personality disorder, unspecified 301.10
Cocaine abuse, unspecified use 305.60 Chronic hypomanic personality disorder 301.11
Cocaine abuse, continuous use 305.61 Chronic depressive personality disorder 301.12
Cocaine abuse, episodic use 305.62 Cyclothymic disorder 301.13
Cocaine abuse, in remission 305.63 Obsessive-compulsive personality disorder 301.4
Amphetamine or related acting sympathomimetic
abuse, unspecified use
305.70 Acute reaction to stress 308
Amphetamine or related acting sympathomimetic
abuse, continuous use
305.71 Predominant disturbance of emotions 308.0
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Appendix 2. Continued
DRUG ABUSE EXCLUDING OPIOIDS ICD-9
MOOD AND ANXIETY
DISORDERS AND DEPRESSION ICD-9
Amphetamine or related acting sympathomimetic
abuse, episodic use
305.72 Predominant disturbance of consciousness 308.1
Amphetamine or related acting sympathomimetic
abuse, in remission
305.73 Predominant psychomotor disturbance 308.2
Antidepressant type abuse, unspecified use 305.80 Other acute reactions to stress 308.3
Antidepressant type abuse, continuous use 305.81 Mixed disorders as reaction to stress 308.4
Antidepressant type abuse, episodic use 305.82 Unspecified acute reaction to stress 308.9
Antidepressant type abuse, in remission 305.83 Adjustment reaction 309
Other mixed or unspecified drug abuse 305.9 Adjustment disorder with depressed mood 309.0
Other, mixed, or unspecified drug abuse, unspecified use 305.90 Adjustment reaction with prolonged depressive reaction 309.1
Other, mixed, or unspecified drug abuse, continuous use 305.91 Adjustment reaction with predominant disturbance of other emotions 309.2
Other, mixed, or unspecified drug abuse, episodic use 305.92 Separation anxiety disorder 309.21
Other, mixed, or unspecified drug abuse, in remission 305.93 Emancipation disorder of adolescence and early adult life 309.22
Specific academic or work inhibition 309.23
Adjustment disorder with anxiety 309.24
Adjustment disorder with mixed anxiety and depressed mood 309.28
Other adjustment reactions with predominant disturbance of other emotions 309.29
Adjustment disorder with disturbance of conduct 309.3
Adjustment disorder with mixed disturbance of emotions and conduct 309.4
Posttraumatic stress disorder 309.81
Adjustment reaction with physical symptoms 309.82
Adjustment reaction with withdrawal 309.83
Other specified adjustment reactions 309.89
Unspecified adjustment reaction 309.9
Depressive disorder, not elsewhere classified 311
Overanxious disorder specific to childhood and adolescence 313.0
Misery and unhappiness disorder specific to childhood and adolescence 313.1
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Appendix 3. Standardized Differences Before and After PS Adjustment in the MarketScan Database
VARIABLE
STANDARDIZED
DIFFERENCE IN
FIRST PS QUINTILE
STANDARDIZED
DIFFERENCE IN
SECOND PS QUINTILE
STANDARDIZED
DIFFERENCE IN THIRD
PS QUINTILE
STANDARDIZED
DIFFERENCE IN FOURTH
PS QUINTILE
STANDARDIZED
DIFFERENCE IN FIFTH
PS QUINTILE
STANDARDIZED
DIFFERENCE BEFORE PS
OVERALL STANDARDIZED
DIFFERENCE AFTER PS
Age .02 .10 .12 .13 –.02 .30 .07
Arthritis .02 .07 .01 .14 .16 .01 .08
Back pain .13 .12 .12 .12 –.05 .25 .09
Benzodiazepine use .06 .05 –.06 .06 .41 .14 .11
Drug abuse excluding opioids –.01 –.02 .02 .06 .20 –.07 .06
Mood/anxiety disorders and depression .00 .01 –.03 .18 .22 –.01 .09
Index year (2010) .03 .00 –.01 .08 .06 –.08 .03
Women –.13 –.02 .12 .21 –.17 –.21 .01
Fractures –.04 –.15 –.03 –.09 –.33 –.18 –.13
Headaches .02 –.02 –.07 –.07 –.22 .01 –.07
Malignancy .02 –.09 –.21 .18 .10 –.12 .00
Musculoskeletal pain .11 .11 .07 .18 .32 .06 .16
Neuropathy .03 .07 .04 .00 –.10 .06 .01
Other –.01 –.01 .04 .04 –.06 –.01 .00
Reproductive system pain .01 .02 –.01 –.02 –.09 .00 –.02
Visceral pain –.04 –.10 –.03 –.02 –.23 –.18 –.09
Wound injury –.04 –.05 –.03 .05 –.25 –.12 –.07
Abbreviation: PS, propensity score.
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Appendix 4. Standardized Differences Before and After PS Adjustment in the Optum Database
VARIABLE
STANDARDIZED
DIFFERENCE IN
FIRST PS QUINTILE
STANDARDIZED
DIFFERENCE IN
SECOND PS QUINTILE
STANDARDIZED
DIFFERENCE IN
THIRD PS QUINTILE
STANDARDIZED
DIFFERENCE IN
FOURTH PS QUINTILE
STANDARDIZED
DIFFERENCE IN FIFTH
PS QUINTILE
STANDARDIZED
DIFFERENCE BEFORE PS
OVERALL
STANDARDIZED DIFFERENCE
AFTER PS
Age .00 .09 .09 .02 –.01 .24 .04
Arthritis .03 .04 .02 .15 .23 .03 .10
Back pain .04 .08 .11 .12 .14 .20 .09
Benzodiazepine use .03 .00 .00 .19 .19 .12 .08
Drug abuse excluding opioids .03 –.01 –.11 .15 .70 –.09 .26
Mood/anxiety disorders and depression .06 –.02 –.06 .02 .59 .02 .15
Index year (2010) –.05 –.01 .03 –.06 .53 –.16 .06
Women .23 .00 –.27 –.21 .32 .27 .01
Fractures –.03 –.10 –.15 .02 .24 –.18 .01
Headaches .03 –.09 –.08 –.04 .36 –.01 .06
Malignancy .06 –.15 –.17 –.29 –.21 –.08 –.14
Musculoskeletal pain .12 .03 .21 .12 .17 .08 .13
Neuropathy .12 .12 .11 –.02 –.10 .14 .05
Other .02 .07 –.02 .11 –.11 .01 .01
Reproductive system pain .05 –.04 –.05 –.08 –.09 .02 –.04
Visceral pain –.06 –.08 –.05 .12 .30 –.22 .08
Wound injury –.03 –.06 .00 –.11 .77 –.12 .22
Abbreviation: PS, propensity score.
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